ADCT analyst estimates
ADC Therapeutics (ADCT) analyst ratings, the average price target and its range, and every firm's latest call.
- 3 firms rate ADCT: 1 buy, 2 hold, 0 sell.
- The average price target is $3.50 from None analysts, from $2.00 to $5.00.
ADCT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jun 4, 2026 | RBC Capital | ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital | $2.00 |
| Jun 4, 2026 | Stephens | ADC Therapeutics price target lowered to $5 from $8 at Stephens | $5.00 |
| Dec 3, 2025 | RBC Capital | RBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness' | $5.00 |
| Nov 12, 2025 | Guggenheim | Guggenheim Reiterates Buy Rating on ADC Therapeutics (ADCT) | $10.00 |
| May 7, 2024 | H.C. Wainwright | ADC Therapeutics (ADCT) PT Lowered to $8 at H.C. Wainwright | $8.00 |
| Mar 13, 2024 | Jefferies | ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies | $13.00 |
| Nov 14, 2022 | Morgan Stanley | Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $7 | $7.00 |
| Sep 9, 2022 | Morgan Stanley | ADC Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley | $11.00 |
| Aug 22, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $20 | $20.00 |